ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2321

Performance of Patient Reported Outcomes in the Assessment of Rheumatoid Arthritis Disease Activity: The Experience of the Espoir Cohort

Hélène Che1, Bernard Combe2, Jacques Morel3, Alain G. Cantagrel4, Laure Gossec5 and Cédric Lukas6, 1Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, 2Rheumatology, Hopital Lapeyronie, Montpellier, France, 3Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, 4Rheumatology, INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Purpan Teaching Hospital, Toulouse, France, 5Rheumatology, Pitié Salpetriere Hospital, Paris, France, 6Hopital Lapeyronie, Montpellier, France

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Disease Activity, patient-reported outcome measures and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Health Services Research Poster III: Patient Reported Outcomes, Patient Education and Preferences

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Activity of rheumatoid arthritis (RA) can be assessed by several outcome measures : joint counts, inflammatory syndrom but also auto-questionnaires such as global patient assessment. The importance of Patient Reported Outcomes (PROs) has been recently put forward. The purpose was to determine whether patient self-assessment can reflect RA disease activity.

Methods: Data from patients included in the early arthritis ESPOIR cohort and fulfilling ACR/EULAR 2010 RA criteria at month 12 were used. The following PROs (Visual Analog Scales for fatigue, pain, patient assessment of disease activity; HAQ; SF36; EMIR-court and RAPID3) and their association with disease activity assessed by DAS28-3 variables, were measured.

DAS28-3 variables (including tender joint count, swollen joint count and erythrocyte sedimentation rate) was preferred to DAS28-4 variables in order to limit the input of subjective and patient-derived appreciation when defining the level of disease activity.

We compared the influence of disease characteristics on each PRO by Student t tests. The association between PROs and disease activity was assessed in several ways: part of explained variance, correlation and performance of each PRO in differentiating low versus higher disease activity states.

Results: 677 patients (83.2%) of the 813 patients of the ESPOIR cohort, were analyzed as they responded to the ACR/EULAR 2010 criteria of RA at month 12.Their mean age was 48.6±12.3 years with 77.4% of female, with a mean duration of disease of 3.41±1.74 months, 60.5% were rheumatoid factor or anti-citrullinated protein positives, 16.4% had anxiodepressive disorder and 15.1% had radiological lesions according to ACR/EULAR criteria. Disease activity assessed by DAS28-3 avriables was, at inclusion, 5.0±1.2, with a decrease during the follow-up.

Whatever the status of disease activity, patients with the lowest disease activity always had significantly less impaired

PROs. All analyzed PROs showed moderate correlations with RA disease activity. The PRO showing the best association with DAS28-3v in determining RA disease activity states, was RAPID3 (Pearson correlation coefficient between 0.45-0.55, explained variance between 30-45%, sensitivity between 69-100% and specificity between 55-78%).

PROs with the highest association with disease activity were global PROs (RAPID3, EMIR-court) followed by those assessing physical function.

Conclusion: Association between PROs and RA disease activity as measured by DAS28-3 variables remains moderate. RAPID3, a global PRO, showed the best association with disease activity compared to the other analyzed PROs.


Disclosure: H. Che, None; B. Combe, None; J. Morel, None; A. G. Cantagrel, None; L. Gossec, None; C. Lukas, None.

To cite this abstract in AMA style:

Che H, Combe B, Morel J, Cantagrel AG, Gossec L, Lukas C. Performance of Patient Reported Outcomes in the Assessment of Rheumatoid Arthritis Disease Activity: The Experience of the Espoir Cohort [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/performance-of-patient-reported-outcomes-in-the-assessment-of-rheumatoid-arthritis-disease-activity-the-experience-of-the-espoir-cohort/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/performance-of-patient-reported-outcomes-in-the-assessment-of-rheumatoid-arthritis-disease-activity-the-experience-of-the-espoir-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology